Delivering substance and drug delivery system using the same

Details Delivering substance and drug delivery system using the same Delivering substance and drug delivery system using the same

2001-04-03

2008-11-25

Kishore, Gollamudi (Department: 1612)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S428000, C514S078000

Reexamination Certificate

active

07455855

ABSTRACT:
An object of the present invention is to prepare substances which are excellent in delivery and enable drugs to be retained in a body effectively over a long period and to construct a drug delivery system using the substances. When the delivering substance which is obtained by reacting polyalkylene glycol or a reactive derivative thereof, a phospholipid and a drug with each other to form covalent bonds is administered systemically or topically, the substance is retained at a target site in a body for a long period, thereby making it possible to sustain drug efficacy over a long period by a single administration.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4804539 (1989-02-01), Guo et al.
patent: 5308624 (1994-05-01), Maincent et al.
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 6060463 (2000-05-01), Freeman
patent: 6171614 (2001-01-01), Chaikof et al.
patent: 6204054 (2001-03-01), Sutton et al.
patent: 6258351 (2001-07-01), Harris
patent: 6602498 (2003-08-01), Shen
patent: 2002/0064520 (2002-05-01), Rozenberg et al.
patent: 2003/0191098 (2003-10-01), D'Amato
patent: 2004/0254197 (2004-12-01), Tasaka et al.
patent: 0 657 463 (1995-06-01), None
patent: 4-221322 (1992-08-01), None
patent: 6-508369 (1994-09-01), None
patent: 8-117586 (1996-05-01), None
patent: 93/00076 (1993-01-01), None
patent: WO 93/24476 (1993-12-01), None
patent: WO 97/19694 (1997-06-01), None
patent: WO 99/39732 (1999-08-01), None
patent: WO 99/48535 (1999-09-01), None
patent: WO 00/07629 (2000-02-01), None
patent: WO 00/35422 (2000-06-01), None
patent: WO 00/45835 (2000-08-01), None
patent: WO 00/64483 (2000-11-01), None
patent: WO 01/51003 (2001-07-01), None
patent: WO 01/74400 (2001-10-01), None
patent: 03/053452 (2003-07-01), None
S.M. Foroutan et al., “The in vitro evaluation of polyethylene glycol esters of hydrocortisone 21-succinate as ocular prodrugs,”Intl. Journal of Pharma., vol. 182, pp. 79 to 92 (1999).
M.E. Szabo et al., “Ischemia and Reperfusion-Induced Histologic Changes in the Rat Retina,”Invest. Ophthal. &Visual Sci., vol. 32, No. 5, pp. 1471 to 1478 (1991).
Daniel W. Drolet et al., “Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys,”Pharmaceutical Research, vol. 17, No. 12, (2000), pp. 1503-1510.
The Eyetech Study Group, “Preclinical and Phase 1A Clinical Evaluation of an Anti-VEGF Pegylated Aptamer (Eye001) for the Treatment of Exudative Age-Related Macular Degeneration,”Retina, vol. 22, No. 2, (2002), pp. 143-151.
Sorbera et al., “Pegaptanib Sodium: Treatment of Age-Related Macular Degeneration Treatment of Diabetic Retinopathy Anti-VEGF Aptamer,”Drugs of the Future, vol. 27, No. 9, (2002), pp. 841-845.

Affiliated with

Also associated with

Rating

Delivering substance and drug delivery system using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Delivering substance and drug delivery system using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivering substance and drug delivery system using the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4029464